FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

ck this box if no longer subject to
tion 16. Form 4 or Form 5
nations may continue. See

(First)

667 MADISON AVENUE, 17TH FLOOR

(Middle)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response:

> > 7. Nature of Indirect Beneficial Ownership (Instr. 4)

Partnership<sup>(3)</sup> Through Partnership<sup>(3)</sup>

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Through

Through Partnership<sup>(3)</sup>

Through

Through

Partnership<sup>(3)</sup>

Partnership<sup>(3)</sup>

Partnership<sup>(3)</sup>

6. Form 4 or F	orm 5	ST		iled pu	rsuant	to Section	16(a	a) of the	e Secu	rities Exchan	ge Act of 3		RSH	IIP			average bur	3235-0 den
		<u>LC</u>								Symbol			(Chec	ck all applic Directo	cable) or		X 10%	Owner
							ransa	action (	Month	/Day/Year)						itle		r (specify v)
RK NY	·	JS 1002	1	4.1	f Amer	ndment, D	ate o	f Origin	al File	d (Month/Day	r/Year)			Form f	filed by	One Rep	orting Per	son
(Sta	ite) (	Zip)												Persor	11			
	Tal	ole I - N	lon-Der	ivativ	e Se	curities	Ac	quire	d, Di	sposed o	f, or Be	neficia	ally (	Owned				
Date				Execution Date,		Transaction Code (Instr. 8)		(D) (Instr. 3, 4 and 5)		5) S B O R	Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature o Indirect Beneficial Ownership (Instr. 4)			
								Code	V	Amount	(A) or (D)	Price						n a
tock <sup>(1)(2)</sup>			03/03	2009				P		2,199	A	\$2.141	16	3,485,7	3,485,752		I Thr Part	
tock <sup>(1)(2)</sup>			03/05	/2009	.009			P		1,248	A	\$2.157	75	3,487,000				Through Partnersl
		Table I												wned				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution if any	on Date,			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		of Securities Underlying		Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirec	Benef Owne t (Instr.	
				Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	or Numb of	er					
\$11.2185	03/03/2009			P		546,000		(	4)	02/15/2011	Common Stock	48,67	70	\$48.125 14,485,000		I	Throu Partne	
\$11.2185	03/04/2009			P		182,000		(	4)	02/15/2011	Common Stock	16,22	23	\$49.5	14,6	67,000	I	Throu Partne
\$11.2185	03/05/2009			P		388,000		(	4)	02/15/2011	Common Stock	34,58	86	\$48.453	15,0	55,000	I	Throu Partne
\$11.2185	03/05/2009			P		485,000		(	4)	02/15/2011	Common Stock	43,23	32	\$50.97	3,59	97,000	I	Throu Partne
		L <u>C</u>																
		,	ddle)															
RK 1	NY	US	10021															
	eporting Person*	(Zip	))		_													
	6. Form 4 or Fiss may continue in 1(b).  Address of R Otech Ca (First SON AVE)  RK NY (Stan Curity (Instr. Conversion or Exercise Price of Derivative Security  \$11.2185  \$11.2185  Address of R Otech Ca (SON AVE)  \$11.2185	Address of Reporting Person* Otech Capital (GP), LI  (First) (C SON AVENUE, 17TH FLC  (State) (C Tal curity (Instr. 3)  2. (State) (C Tal curity (Instr. 3)  2. (State) (Month/Day/Year)  \$11.2185 03/03/2009  \$11.2185 03/05/2009  \$11.2185 03/05/2009  \$11.2185 03/05/2009  Address of Reporting Person* Otech Capital (GP), LI  (First)  SON AVENUE, 17TH FLC  RK NY  (State)  Address of Reporting Person*	6. Form 4 or Form 5 is may continue. See in 1(b).  Address of Reporting Person* Otech Capital (GP), LLC  (First) (Middle)  SON AVENUE, 17TH FLOOR  RK NY US 1002  (State) (Zip)  Table I - N  curity (Instr. 3)  Table I - N  curity (Instr. 3)  2. (State) (Zip)  Table I - N  curity (Instr. 3)  1.1.2185 03/03/2009  \$11.2185 03/03/2009  \$11.2185 03/05/2009  \$11.2185 03/05/2009  \$11.2185 03/05/2009  Address of Reporting Person* Otech Capital (GP), LLC  (First) (Middle)  (Month/IDay/Year) (Month/IDay/Year)  (Month/IDay/Year) (Middle)  SON AVENUE, 17TH FLOOR  RK NY US  (State) (Zip)  Address of Reporting Person*  Otech Capital (GP), LLC  (State) (Zip)	6. Form 4 or Form 5 is smay continue. See in 1(b).  Address of Reporting Person* Otech Capital (GP), LLC  (First) (Middle) SON AVENUE, 17TH FLOOR  RK NY US 10021  (State) (Zip)  Table II - Non-Der Curity (Instr. 3)  Table III - Deriv (e.g., 1000)  2. Transaction Date (e.g., 1000) Table III - Deriv (e.g., 1000)  \$11.2185   03/03/2009   \$11.2185   03/03/2009   \$11.2185   03/05/2009   \$11.2185   03/05/2009   \$11.2185   03/05/2009    Address of Reporting Person* Otech Capital (GP), LLC  (First) (Middle)  SON AVENUE, 17TH FLOOR  RK NY US 10021  Address of Reporting Person* Otech Capital (GP), LLC  (State) (Zip)	6. Form 4 or Form 5 is may continue. See in 1(b). Filed purpose in 1(b). Filed	6. Form 4 or Form 5 is may continue. See in 1(b).  Filed pursuant or Section 1(b).  Filed pursuant or Section 1(b).  Filed pursuant or Section 2 is may continue. See in 1(b).  Address of Reporting Person*  Table I - Non-Derivative Security (Instr. 3)  Table II - Non-Derivative Security (Instr. 3)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (Month/Day/Year)  Table II - Derivative Security (Month/Day/Year)  Address of Reporting Person*  Address of Reporting Person*  Address of Reporting Person*  RK NY US 10021  Filed pursuant or Section 2. Suspension 3. Date of 03/03/2009  4. If Americal Americal American 3. Deemed Execution Date, if any (Month/Day/Year) Price of Derivative Security (Month/Day/Year)  \$11.2185 03/03/2009 P  \$11.2185 03/03/2009 P  \$11.2185 03/05/2009 P	Serial   Address of Reporting Person   Table   I - Non-Derivative Securities   Code (Inst.)	Filed pursuant to Section 16(6 or Section 30(n) of the Sinay continue. See	S. Form 4 or Form 5   San ya continue. See   12(b)   Filled pursuant to Section 15(a) of the Investment of Section 30(h) of the Investment of Section 15(a) of the Investment of Section 30(h) of the Investment of Section 15(a) o	Serond or Form 5   Serond 10(a)   Filed pursuant to Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Reporting Person   10(b)   Section 30(h) of the Investment C address of Rep	6. Form or Form 5 is now confine. See a 12(0).  Filed pursuant to Section 15(6) of the Securities Exchan or Section 30(h) of the Investment Company Act or Section 30(h) or Sectio	C. Form 4 or Form 5   Filed pursuant to Section 16(a) of the Securities Exchange Act of 1940	6. Form 4 or Form 5   Filed pursuant to Section 15(a) of the Securities Exchange Act of 1934 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t) of the Investment Company Act of 1930 or Section 30(t)	S. Form 4 p Fem 5	Field pursuant to Section 15(a) of the Securities Exchange Act of 1940	Contract organisation   Several Contract organisation   Seve	Schmarter   Security   Security	Content of programs   Content of Content   C

(Street) NEW YORK	NY	US 10021							
(City)	(State)	(Zip)							
1. Name and Address of Reporting Person*  BAKER FELIX									
(Last)	(First)	(Middle)							
667 MADISON AVENUE, 17TH FLOOR									
(Street)									
NEW YORK	NY	US 10021							
(City)	(State)	(Zip)							

## **Explanation of Responses:**

- 1. In addition to Baker Biotech Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Julian C. Baker is a Director of the Issuer. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were members of a group of such shareholders. (Continued in footnote 2).
- 2. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
- 3. Represents securities owned directly by 667, L.P., the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP), LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.
- 4. Immediately.

/s/ Julian C. Baker, as Managing

Member of Baker Biotech 03/05/2009

<u>Capital (GP), LLC</u> /s/ Julian C. Baker

03/05/2009

<u>/s/ Felix J. Baker</u> 03/05/2009

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.